New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround ...
(PR-inside.com) Jensen, who as CEO led Nasdaq-listed biotech Allarity Therapeutics' refocusing around a single lead asset, cites Valion's rare combination of government funding, FDA designations, human safety data and wholly owned U.S. manufacturing SAN ANTONIO, TX / ACCESS Newswire / October 5, 2026 / Valion Bio, Inc.…
Short extract only — this publisher licenses its text. Read the full release at the source.
Free plan · Plus CA$29 or Pro CA$99/month


